BIOMAT Database Logo BIOMAT Database Logo

Genetically determined polymorphisms in drug oxidation. 1986

E Jacqz, and S D Hall, and R A Branch

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008617 Mephenytoin An anticonvulsant effective in tonic-clonic epilepsy (EPILEPSY, TONIC-CLONIC). It may cause blood dyscrasias. Methoin,Methyl Phenetoin,5-Ethyl-3-Methyl-5-Phenylhydantoin,Mefenetoin,Mesantoin,Phenantoin,5 Ethyl 3 Methyl 5 Phenylhydantoin,Phenetoin, Methyl
D008862 Microsomes, Liver Closed vesicles of fragmented endoplasmic reticulum created when liver cells or tissue are disrupted by homogenization. They may be smooth or rough. Liver Microsomes,Liver Microsome,Microsome, Liver
D010084 Oxidation-Reduction A chemical reaction in which an electron is transferred from one molecule to another. The electron-donating molecule is the reducing agent or reductant; the electron-accepting molecule is the oxidizing agent or oxidant. Reducing and oxidizing agents function as conjugate reductant-oxidant pairs or redox pairs (Lehninger, Principles of Biochemistry, 1982, p471). Redox,Oxidation Reduction
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D011110 Polymorphism, Genetic The regular and simultaneous occurrence in a single interbreeding population of two or more discontinuous genotypes. The concept includes differences in genotypes ranging in size from a single nucleotide site (POLYMORPHISM, SINGLE NUCLEOTIDE) to large nucleotide sequences visible at a chromosomal level. Gene Polymorphism,Genetic Polymorphism,Polymorphism (Genetics),Genetic Polymorphisms,Gene Polymorphisms,Polymorphism, Gene,Polymorphisms (Genetics),Polymorphisms, Gene,Polymorphisms, Genetic
D003647 Debrisoquin An adrenergic neuron-blocking drug similar in effects to GUANETHIDINE. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism. Debrisoquine,Tendor
D004364 Pharmaceutical Preparations Drugs intended for human or veterinary use, presented in their finished dosage form. Included here are materials used in the preparation and/or formulation of the finished dosage form. Drug,Drugs,Pharmaceutical,Pharmaceutical Preparation,Pharmaceutical Product,Pharmaceutic Preparations,Pharmaceutical Products,Pharmaceuticals,Preparations, Pharmaceutical,Preparation, Pharmaceutical,Preparations, Pharmaceutic,Product, Pharmaceutical,Products, Pharmaceutical
D004798 Enzymes Biological molecules that possess catalytic activity. They may occur naturally or be synthetically created. Enzymes are usually proteins, however CATALYTIC RNA and CATALYTIC DNA molecules have also been identified. Biocatalyst,Enzyme,Biocatalysts
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

E Jacqz, and S D Hall, and R A Branch
[Clinical sequelae of genetically determined polymorphisms of drug oxidation].
January 1992, Polski tygodnik lekarski (Warsaw, Poland : 1960),
E Jacqz, and S D Hall, and R A Branch
Genetically determined variability in drug metabolism: dual slow acetylation and drug oxidation traits.
July 1979, Lancet (London, England),
E Jacqz, and S D Hall, and R A Branch
Genetically determined oxidation polymorphism and drug hepatotoxicity. Study of 51 patients.
March 1989, Journal of hepatology,
E Jacqz, and S D Hall, and R A Branch
Genetically determined polymorphisms of erythrocyte enzymes in man.
January 1968, Advances in clinical chemistry,
E Jacqz, and S D Hall, and R A Branch
Genetically determined impaired drug sulphoxidation.
April 1981, Lancet (London, England),
E Jacqz, and S D Hall, and R A Branch
Genetically determined debrisoquine oxidation capacity in bladder cancer.
September 1984, Carcinogenesis,
E Jacqz, and S D Hall, and R A Branch
Genetically determined sparteine oxidation polymorphism in a Polish population.
January 1994, European journal of clinical pharmacology,
E Jacqz, and S D Hall, and R A Branch
Genetically determined variability in acetylation and oxidation. Therapeutic implications.
April 1985, Drugs,
E Jacqz, and S D Hall, and R A Branch
The non-human primate: a possible model for human genetically determined polymorphisms in oxidative drug metabolism.
August 1988, Molecular pharmacology,
E Jacqz, and S D Hall, and R A Branch
Genetically determined oxidation capacity and the disposition of debrisoquine.
April 1983, British journal of clinical pharmacology,
Copied contents to your clipboard!